PMID- 26791678
OWN - NLM
STAT- MEDLINE
DCOM- 20170329
LR  - 20230829
IS  - 1538-7836 (Electronic)
IS  - 1538-7836 (Linking)
VI  - 14
IP  - 4
DP  - 2016 Apr
TI  - The influence of corticosteroids on hemostasis in healthy subjects.
PG  - 716-23
LID - 10.1111/jth.13265 [doi]
AB  - BACKGROUND: Corticosteroids have been associated with an increased risk of venous 
      thromboembolism in patients treated for inflammatory diseases. It is unclear 
      whether the thrombotic risk is induced by the inflammation of the underlying 
      inflammatory diseases or whether corticosteroids are prothrombotic as well. 
      Considering the widespread use of corticosteroids in clinical practise, it is 
      critical to know whether corticosteroids enhance coagulation. OBJECTIVE: To 
      investigate whether a 10-day prednisolone burst therapy activates hemostasis in 
      healthy individuals. METHODS: Healthy subjects received either 0.5 mg kg(-1) 
      day(-1) of oral prednisolone or placebo. Venous blood was collected at baseline, 
      day 1 and day 10 and tested for thrombin-antithrombin complexes (TATc), D-dimer, 
      plasmin-alpha2-antiplasmin complexes (PAPc), plasminogen-activator inhibitor 
      type-1 (PAI-1), von Willebrand factor (VWF) and thrombin generation (peak 
      thrombin, velocity index and endogenous thrombin potential [ETP]). RESULTS: 
      Fifteen subjects received prednisolone and 16 placebo (median age 29 vs. 22 
      years, female subjects 33% vs. 56%, respectively). Peak thrombin and velocity 
      index were higher in the placebo group at baseline. After 10 days of treatment, 
      peak thrombin, velocity index, PAI-1 and VWF increased in the oral prednisolone 
      group as compared with the placebo group (15.8 [SD 16.3] vs. -0.1 [SD 16.1], 41.2 
      [SD 41.3] vs. -2.3 [SD 42.7], 18.0 [IQR 8.0-37.0] vs. 0.5 [IQR -18.5-13.0], 4.0 
      [IQR -1.0-12.0] vs. 0.0 [IQR -2.5-1.5], respectively). No changes were observed 
      for TATc, ETP, PAPc and D-dimer. CONCLUSIONS: Oral prednisolone induces a 
      procoagulant state in healthy subjects, suggesting that corticosteroid treatment 
      may increase the thromboembolic risk in patients with inflammatory diseases.
CI  - (c) 2016 International Society on Thrombosis and Haemostasis.
FAU - Majoor, C J
AU  - Majoor CJ
AD  - Department of Respiratory Medicine, Academic Medical Center, Amsterdam, the 
      Netherlands.
FAU - Sneeboer, M M S
AU  - Sneeboer MM
AD  - Department of Respiratory Medicine, Academic Medical Center, Amsterdam, the 
      Netherlands.
FAU - de Kievit, A
AU  - de Kievit A
AD  - Department of Respiratory Medicine, Academic Medical Center, Amsterdam, the 
      Netherlands.
FAU - Meijers, J C M
AU  - Meijers JC
AUID- ORCID: 0000-0002-4198-6780
AD  - Department of Experimental Vascular Medicine, Academic Medical Center, Amsterdam, 
      the Netherlands.
AD  - Department of Plasma Proteins, Sanquin Research, Amsterdam, the Netherlands.
FAU - van der Poll, T
AU  - van der Poll T
AD  - Center of Experimental and Molecular Medicine, Academic Medical Center, 
      Amsterdam, the Netherlands.
FAU - Lutter, R
AU  - Lutter R
AD  - Department of Respiratory Medicine, Academic Medical Center, Amsterdam, the 
      Netherlands.
AD  - Department of Experimental Immunology, Academic Medical Center, Amsterdam, the 
      Netherlands.
FAU - Bel, E H
AU  - Bel EH
AD  - Department of Respiratory Medicine, Academic Medical Center, Amsterdam, the 
      Netherlands.
FAU - Kamphuisen, P W
AU  - Kamphuisen PW
AD  - Department of Vascular Medicine, University Medical Center Groningen, Groningen, 
      the Netherlands.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20160218
PL  - England
TA  - J Thromb Haemost
JT  - Journal of thrombosis and haemostasis : JTH
JID - 101170508
RN  - 0 (Adrenal Cortex Hormones)
RN  - 0 (Fibrin Fibrinogen Degradation Products)
RN  - 0 (Plasminogen Activator Inhibitor 1)
RN  - 0 (SERPINE1 protein, human)
RN  - 0 (fibrin fragment D)
RN  - 0 (von Willebrand Factor)
RN  - 9PHQ9Y1OLM (Prednisolone)
RN  - EC 3.4.21.5 (Thrombin)
SB  - IM
MH  - Administration, Oral
MH  - Adrenal Cortex Hormones/*adverse effects
MH  - Adult
MH  - Blood Coagulation/drug effects
MH  - Double-Blind Method
MH  - Female
MH  - Fibrin Fibrinogen Degradation Products/chemistry
MH  - Fibrinolysis/drug effects
MH  - Healthy Volunteers
MH  - Hemostasis/*drug effects
MH  - Humans
MH  - Inflammation/complications
MH  - Male
MH  - Plasminogen Activator Inhibitor 1/blood
MH  - Prednisolone/*adverse effects
MH  - Thrombin/chemistry
MH  - Venous Thromboembolism/chemically induced
MH  - Young Adult
MH  - von Willebrand Factor/chemistry
OTO - NOTNLM
OT  - corticosteroids
OT  - fibrinolysis
OT  - healthy volunteers
OT  - hemostasis
OT  - pulmonary embolism
OT  - therapy
EDAT- 2016/01/23 06:00
MHDA- 2017/03/31 06:00
CRDT- 2016/01/22 06:00
PHST- 2015/10/13 00:00 [received]
PHST- 2016/01/07 00:00 [accepted]
PHST- 2016/01/22 06:00 [entrez]
PHST- 2016/01/23 06:00 [pubmed]
PHST- 2017/03/31 06:00 [medline]
AID - S1538-7836(22)04641-4 [pii]
AID - 10.1111/jth.13265 [doi]
PST - ppublish
SO  - J Thromb Haemost. 2016 Apr;14(4):716-23. doi: 10.1111/jth.13265. Epub 2016 Feb 
      18.